John Greene bought $314K of CRISPR Therapeutics AG (CRSP)
Executed Feb 26 2025, disclosed Feb 28 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 28 2025), the stock returned -13.2% (delay-adjusted); from the execution session (Feb 26 2025), -12.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
John Greene (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in CRISPR Therapeutics AG (CRSP). Across 1 priced purchase filing, the average 21-session return was -12.7% from execution and -13.2% from disclosure (delay-adjusted; derived). The largest single filing was $314K of CRSP (7,000 sh × $44.85, as filed), executed Feb 26 2025.
Healthcare · CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered R…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→